Hospital Albert Einstein

einstein.br

The birth of the Brazilian Jewish Beneficent Society Albert Einstein in the 1950s resulted from the commitment of the Jewish community to offer the Brazilian population a reference in the quality of medical practice. But the Society wanted to go beyond simply building a hospital. And so it was done, built with resources from donations and the work of a group of dedicated people, Hospital Israelita Albert Einstein was inaugurated in 1971.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

EMERGENT BIOSOLUTIONS COMPLETES ACQUISITION OF EXCLUSIVE WORLDWIDE RIGHTS TO TEMBEXA® FIRST FDA-APPROVED SMALLPOX ORAL ANTIVIRAL FOR ALL AGES

TEMBEXA and Smallpox | September 27, 2022

news image

Emergent BioSolutions Inc. announced that it has completed its acquisition of exclusive worldwide rights to TEMBEXA® the first oral antiviral approved by the U.S. Food and Drug Administration for all age groups for the treatment of smallpox, from Chimerix. TEMBEXA was approved in June 2021 and is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. The completion of the acquisition follows the satisfaction or waiver by the ...

Read More

Medical

NORDIC BIOSCIENCE AND ROCHE DIAGNOSTICS STRENGTHEN COLLABORATION FOR DEVELOPMENT OF BIOMARKERS FOR CHRONIC DISEASES

Nordic Bioscience | June 17, 2022

news image

Nordic Bioscience, a growing biomarker company, today announced the strengthening of its ongoing collaboration with Roche Diagnostics for the development of proprietary biomarkers involved in tissue breakdown and build-up. Nordic Bioscience is a world leader in Extra Cellular Matrix (ECM) biomarker development that can provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting.<...

Read More

MedTech

SEEGENE DEVELOPS WORLD'S FIRST COVID-19 DIAGNOSTIC VARIANT TEST CAPABLE OF IDENTIFYING MULTIPLE MUTANT VARIATIONS

Seegene | February 01, 2021

news image

South Korea's biotechnology firm Seegene (KQ096530) said Monday it built up the world's first COVID-19 diagnostic variation test, fit for screening COVID-19 and recognizing various mutant variations in a single reaction. Seegene's new variation test, the 'Allplex™ SARS-CoV-2 Variants I Assay,' can detect and separate virus variations, including those discovered to be more contagious and fatal. The new variation test identifies COVID-1...

Read More

MedTech

GREENLIGHT BIOSCIENCES AND SAMSUNG BIOLOGICS COMPLETE FIRST COMMERCIAL-SCALE ENGINEERING RUN FOR MRNA COVID-19 VACCINE

Samsung Biologics | August 02, 2022

news image

GreenLight Biosciences a biotechnology company dedicated to making ribonucleic acid products affordable and accessible for human health and agriculture, and Samsung Biologics a leading global CDMO providing fully integrated end-to-end contract development and manufacturing services, announced the successful completion of the first commercial-scale engineering run for the companies' mRNA production partnership. Since the announcement of the strategic partnership between GreenLi...

Read More
news image

Cell and Gene Therapy

EMERGENT BIOSOLUTIONS COMPLETES ACQUISITION OF EXCLUSIVE WORLDWIDE RIGHTS TO TEMBEXA® FIRST FDA-APPROVED SMALLPOX ORAL ANTIVIRAL FOR ALL AGES

TEMBEXA and Smallpox | September 27, 2022

Emergent BioSolutions Inc. announced that it has completed its acquisition of exclusive worldwide rights to TEMBEXA® the first oral antiviral approved by the U.S. Food and Drug Administration for all age groups for the treatment of smallpox, from Chimerix. TEMBEXA was approved in June 2021 and is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. The completion of the acquisition follows the satisfaction or waiver by the ...

Read More
news image

Medical

NORDIC BIOSCIENCE AND ROCHE DIAGNOSTICS STRENGTHEN COLLABORATION FOR DEVELOPMENT OF BIOMARKERS FOR CHRONIC DISEASES

Nordic Bioscience | June 17, 2022

Nordic Bioscience, a growing biomarker company, today announced the strengthening of its ongoing collaboration with Roche Diagnostics for the development of proprietary biomarkers involved in tissue breakdown and build-up. Nordic Bioscience is a world leader in Extra Cellular Matrix (ECM) biomarker development that can provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting.<...

Read More
news image

MedTech

SEEGENE DEVELOPS WORLD'S FIRST COVID-19 DIAGNOSTIC VARIANT TEST CAPABLE OF IDENTIFYING MULTIPLE MUTANT VARIATIONS

Seegene | February 01, 2021

South Korea's biotechnology firm Seegene (KQ096530) said Monday it built up the world's first COVID-19 diagnostic variation test, fit for screening COVID-19 and recognizing various mutant variations in a single reaction. Seegene's new variation test, the 'Allplex™ SARS-CoV-2 Variants I Assay,' can detect and separate virus variations, including those discovered to be more contagious and fatal. The new variation test identifies COVID-1...

Read More
news image

MedTech

GREENLIGHT BIOSCIENCES AND SAMSUNG BIOLOGICS COMPLETE FIRST COMMERCIAL-SCALE ENGINEERING RUN FOR MRNA COVID-19 VACCINE

Samsung Biologics | August 02, 2022

GreenLight Biosciences a biotechnology company dedicated to making ribonucleic acid products affordable and accessible for human health and agriculture, and Samsung Biologics a leading global CDMO providing fully integrated end-to-end contract development and manufacturing services, announced the successful completion of the first commercial-scale engineering run for the companies' mRNA production partnership. Since the announcement of the strategic partnership between GreenLi...

Read More